UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
Phase 1
Completed
- Conditions
- Immune System DiseasesAutoimmune DiseasesLupus Erythematosus, SystemicSkin and Connective Tissue DiseasesConnective Tissue Disease
- Interventions
- Biological: CDP7657Other: Placebo
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 44
- Registration Number
- NCT01093911
- Locations
- 🇩🇪
4, Hannover, Germany
🇩🇪1, Berlin, Germany
🇧🇪6, Leuven, Belgium
Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Sperm Quality
- Interventions
- Biological: Certolizumab pegolBiological: Placebo
- First Posted Date
- 2010-03-23
- Last Posted Date
- 2011-09-05
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT01091220
Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2012-05-22
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 50
- Registration Number
- NCT01059903
To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate
Phase 1
Completed
- Conditions
- ArthritisRheumatoid Arthritis
- Interventions
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 40
- Registration Number
- NCT01009242
Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Certolizumab pegolOther: Placebo
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 224
- Registration Number
- NCT00993668
Human Pharmacology Study (Keppra Dry Syrup Bioequivalence Study)
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 26
- Registration Number
- NCT00985348
Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 40
- Registration Number
- NCT00957944
Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 461
- Registration Number
- NCT00955357
- Locations
- 🇧🇬
703, Blagoevrad, Bulgaria
🇧🇬706, Pleven, Bulgaria
🇧🇬700, Sofia, Bulgaria
A Multicenter, Open-Label Study To Investigate The Safety And Pharmacokinetics Of Lacosamide In Children With Partial Seizures
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 47
- Registration Number
- NCT00938431
- Locations
- 🇺🇸
012, Tampa, Florida, United States
🇺🇸005, Durham, North Carolina, United States
🇺🇸020, Norfolk, Virginia, United States
Study in Healthy Volunteers to Prove That 2 Rotigotine Patches From Different Manufacturing Processes Deliver Equivalent Drug Amount to the Body.
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 52
- Registration Number
- NCT00881894
© Copyright 2025. All Rights Reserved by MedPath